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Abstract
Background: Identification of urinary biomarkers for detection of bladder cancer recurrence would be beneficial to
minimize the frequency of cystoscopy. Our objective was to determine the usability of urine content of mRNA in
the detection and prediction of bladder cancer recurrence.
Methods: We analyzed 123 prospectively cross-sectional collected urine samples from 117 patients with bladder
cancer (12 incident cancers and 111 control visits). We used biopsies from cystoscopies as diagnostic criteria for
recurrence, and followed the patients for a median time of 28.5 months (range 0-44 months). We measured the
levels of hTERT, SENP1, PPP1CA, and MCM5 mRNA in urine by q-RT- PCR.
Results: We found significant differences in urinary content of hTERT (p < 0.001), SENP1 (p < 0.001), MCM5 (p <
0.001), and PPP1CA (p < 0.001) transcripts, when comparing urine samples from patients with and without tumor
present in the bladder. We obtained sensitivity and specificity values for hTERT: 63/73, SENP1: 56/78, MCM5: 63/66,
and PPP1CA: 69/63, respectively. Including follow-up data resulted in sensitivity and specificity values for hTERT:
62/84, SENP1:53/84, MCM5: 61/73, and PPP1CA: 65/66. Interestingly, at non-tumor visits the urinary content of
especially hTERT (p = 0.0001) and MCM5 (p = 0.02) were significantly associated with subsequent tumour
recurrence. Combining the markers with cytology improved the detection. The best combination was hTERT and
cytology with a sensitivity of 71% and a specificity of 86% after follow-up. Further prospective validation or
registration studies needs to be carried out before clinical use.
Conclusions: We could use the urinary content of hTERT, SENP1, PPP1CA, and MCM5 to detect bladder cancer
recurrence. All markers showed a higher sensitivity than cytology. The detection rate improved when including
cytology results, but also the combination of hTERT and MCM5 increased the detection rate. Furthermore, hTERT
and MCM5 levels predicted subsequent tumor recurrences.
Background
Non-muscle invasive bladder cancer is characterized by
frequent tumor recurrences. Today the standard follow-
up consists of cystoscopy combined with cytological
examination at an interval of 3 to 6 months depending
on tumor malignancy and previous recurrence rate.
Cystoscopic examinations are unpleasant, time consum-
ing, expensive, and may have serious side effects such as
infections and damage to urethra [1]. Cytology is char-
acterized by a high specificity (0.83-0.997) but a low
sensitivity (0.20-0.53) [2]. It has been calculated that
bladder cancer invokes the highest cost per patient from
diagnosis to death; in the US calculated to exceed 3.4
billion dollars annually [3]. Bladder tumor markers may
reduce these costs significantly.
Current FDA approved assays available for bladder
cancer detection are: BTA stat, BTA TRAK, NMP22,
FDP, Urovysion, and ImmunoCyt. One of the best char-
acterized and more promising biomarkers is telomerase
(hTERT) [4-8]. hTERT is a ribonucleoprotein enzyme
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mosomes in order to compensate for sequence loss dur-
ing DNA replication [7]. Telomerase is inactive in
mature cells, however, telomerase activity can be
detected in 85-90% of all primary human cancers [9]
and reactivation immortalize cells [10-12]. hTERT is
described as superior to cytology in regard to sensitivity,
but false positive results are seen in benign urothelial
conditions [2,7].
Other potential biomarkers like MCM5, PPP1CA,a n d
SENP1 are less thoroughly described. MCM5 drives the
formation of pre-replicative complexes in the first key
event during G1 phase and is essential for cell prolifera-
tion. MCM5 is detectable in urine and associated with
adverse outcome [13,14]. PPP1CA is involved in pRB
dephosphorylation [15,16] and ceramide accumulation
induced by RAS, as a response to oncogenic stress
increases PPP1CA activity, pRB phosphorylation and
onset of p53 induced arrest, and thereby contributes to
tumor suppression [15,16]. SENP1 is a SUMO-specific
peptidase shown to desumorylate promyelocytic leuke-
mia (PML) protein [17]. PML protein is a tumor sup-
pressor protein requiring SUMOylation [18,19]. PML
bodies of an altered morphology have been described in
alternative lengthening of telomeres (ALT) [20]. SENP1
might function as a marker for tumors in which telo-
meres were maintained by ALT, as not all, especially
invasive tumors, are hTERT positive [21].
Here we evaluated the diagnostic value of measuring
the urinary content of hTERT, MCM5, PPP1CA,a n d
SENP1 mRNAs for detection of tumor recurrence.
Methods
Patient material
Urine samples were collected prospectively at the
Department of Urology at Aarhus University Hospital,
Skejby. Informed consent was obtained from all patients
involved, and the protocol was approved by the Scienti-
fic Ethics Committee in Aarhus County. We collected
50 mL urine at regular follow-up visits. All patients
diagnosed with bladder cancer were included in the
study. In total urine samples from: 54 patients with
biopsy proven recurrent bladder cancer at sampling, 59
patients with a previous bladder cancer and no tumor at
sampling, and 10 patients with a primary bladder cancer
at sampling time. The tumor biopsies were graded
according to Bergkvist (Table 1). Twenty-two of the
patients received Bacille Calmette-Guérin (BCG), two
patients received Mitomycin (MMC), and six patients
received radiotherapy (Table 2). Eleven urine specimens
were from patients with muscle invasive tumors.
In the initial analysis recurrence was defined by biopsy
verified tumor. But since cystoscopy is not 100% sensi-
tive, we also analyzed the data using combined criteria
of either biopsy verified tumor in the bladder or atypical
malignant cells grade 2 or 3 in the urine [1,22] as recur-
rence. Furthermore, follow-up data on the patients was
used to make a longitudinal analysis [1,23]. In the statis-
tical analysis we grouped recurrent cases together with
the primary cases. In the data analysis we defined posi-
tive cytology as presence of atypical cells grade 2 or 3 in
the urine (see Additional file 1) [24,25].
Urine sampling and RNA processing
2 mL of EDTA were added within 15 minutes after
urine voiding, and the urine was stored at 4°C for a
maximum of two hours until further processing. Then
the urine was centrifuged and washed with PBS twice
and the cell pellet was lysed in RLT buffer from QIA-
GEN. Immediately after lysis the samples were stored at
minus 80°C. RNA processing was performed using
QIAshredder (QIAGEN) and thereafter extracted using
the RNeasy mini kit (QIAGEN) and eluted in150 μL
RNase free water and stored at minus 80°C. The RNA
quality was assessed by use of Eukaryote Total RNA
picochips (Agilent Technologies).
Quantitative polymerase chain reaction
Analysis of hTERT, SENP1,a n dPPP1CA was carried out
by a combined cDNA and PCR amplification using
TaqMan48 from Roche Molecular Systems, Pleasanton,
CA. Analysis of the MCM5 transcripts was performed in
89 of the 123 samples due to limitation in material. For
this we concentrated the remaining RNA using RNeasy
MinElute Cleanup kit (QIAGEN) and used Sensiscript RT
kit (QIAGEN) for cDNA synthesis using random nonamer
primers. QPCR was performed using an ABI 7500 with
Taqman probes for MCM5 (Hs00198823_m1). The
samples were diluted 1:5 and all samples were analyzed in
triplicates (see Additional file 2)
Statistical analysis
We used Stata 10.0 statistical analysis software (Stata
Corporation, College Station, TX, USA) for calculation
of ROC curves, nonparametric Wilcoxon rank-sum
and Kruskal- Wallis tests for differences in parameters,
Table 1 Distribution of tumor stage and grade among all
included patients in the study
Grade and stage
distribution
None Grade 1 Grade 2 Grade 3 Total
No tumor 59 59
Ta 10 26 7 43
T1 1 5 6
T2-4 1 10 11
CIS 4 4
Total 59 10 28 26 123
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Kaplan-Meier survival plots.
Results
Characterization of the patients and the urine samples
We collected 123 urine samples from 117 patients dur-
ing a two year period. The median follow-up time was
28.5 months (range 0-44 months). Including the follow-
up period, 77 patients showed tumor recurrence. When
comparing the urine samples from primary visits, recur-
rent visits, and non-recurrent visits we did not find any
significant differences in RNA quality, age of the
patients, follow up time, nor in previous tumor charac-
teristics (Table 2). Notably, we observed much higher
RNA concentrations in primary cancers than in recur-
rent and non-recurrent cases (p = 0.0001), as well as dif-
ferences in pellet-size (p = 0.021), in line with earlier
studies [1,22,23].
The recurrence risk score for the non muscle-invasive
tumors was calculated using EORTC risk tables [26].
We used the previous tumor combined with a history of
T1 and T2-4 as a reference to calculate a risk score for
recurrence and progression. We found no differences in
risk between patients with recurrence and those without
recurrence using EORTC risk tables (Table 2).
Analysis of RT-PCR data using biopsy proven recurrence
at sampling
We performed quantitative RT-PCR to measure the
transcript level of hTERT, PPP1CA, SENP1,a n dMCM5
in the urine samples. In the first approach we used the
cystoscopy result as the gold standard for recurrence
and classified the patients accordingly. After applying
optimal cut-off points using ROC curves (examples
shown in Figure 1), we observed the following sensitivity
and specificity measures for the analyzed markers:
hTERT (62.5% sensitivity, 72.9% specificity, p < 0.001);
PPP1CA (68.8% sensitivity and 62.7% specificity, p <
0.001); SENP1 (56.3% sensitivity and 78% specificity, p <
0.001); and MCM5 (62.5% sensitivity and 65.9% specifi-
city, p = 0.008). Cytology had a 48.3% sensitivity and
79.3% specificity, p = 0.002 (Table 3). We combined the
markers with cytology in order to improve our test
results and found that especially the combination of
hTERT and cytology resulted in a sensitivity of 73.3%
and a specificity of 74.1% (Table 3).
Analysis of RT-PCR data using follow-up information
In the second approach we included follow-up informa-
tion and we found that nine of the 16 tumors formerly
classified as false positive turned out to be true positive,
raising the specificity to 83.7% for hTERT (see Table 4).
All patients with positive cy t o l o g yw e r ed i a g n o s e dw i t h
a tumor in the follow-up period. The median time from
urine sampling to tumor diagnosis was 12.3 month for
this group (range 3-23). Sensitivity and specificity of all
markers using these criteria are listed in Additional file
3. The specificity and especially the sensitivity are higher
than observed when only using tumor diagnosis based
on cystoscopy information. Furthermore, when we stra-
tified the dataset according to grade, we found a positive
correlation between our markers and high grade (Addi-
tional file 4).
Performance compared to cytology and in combination
Interestingly hTERT, MCM5, and PPP1CA were positive
in all 7 samples with atypical cells grade 2 or grade 3
that were diagnosed as non-recurrent because no
tumors were found at cystoscopy; however, all were
diagnosed with a tumor in the follow-up period. We
also compared our results to cytology after stratifying
the results according to grade using only cystoscopy as
Table 2 Patient and tumor characteristic for patients with recurrent and non-recurrent tumors
Recurrent and primary Non-recurrent P-value (Mann-Whitney)
EORTC 1 year 0.33 0.29 0.12
Recurrence score* N = 99 5 years 0.55 0.51 0.13
EORTC 1 year 0.032 0.029 0.16
Progression score* N = 99 5 years 0.11 0.099 0.16
Age at urine sample (years) 69 71 0.18
Male/female ratio 57/20 35/11
Follow-up time (months) 28 29 0.75
Leucocyte pos/neg ratio 5/68 5/40
BCG or MMC treatment before urine sampling 13 11 0.82
Average pellet size** 1.39 1.41 0.95
Average RNA quality (RIN) 3.70 3.83 0.89
Average RNA conc. (pg/μL) 5995 (32-169186) 7990 (5-117671) 0.0029
* EORTC scores are only calculated for non-muscle invasive tumors. There are 51 urine samples in the non-muscle invasive recurrent group and 48 urine samples
in the no-tumor group.
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lation between grade and sensitivity for all markers and
cytology (Additional file 4). The sensitivity was higher
for all markers measured in the study compared to
cytology, but the highest specificity was observed for
cytology. For grade 1 and grade 2 tumors the markers
were all superior to cytology. Combination of markers
gave the best result for MCM5 and hTERT with a sensi-
tivity of 76% and a specificity of 77% (Additional file 3).
W h e na p p l y i n gac u t - o f fw i t ho n em a r k e rp o s i t i v ei t
gave a sensitivity of 72% and a specificity of 71%. AUC
were 0.72 (Additional file 3).
Prognostic value at non-recurrent visits
We evaluated the prognostic value of the markers at non-
r e c u r r e n tv i s i t s .W ef o u n dt h a te s p e c i a l l yhTERT and
MCM5 expression were able to significantly add informa-
tion to the diagnosis obtained by cystoscopy and cytology
as seen in Figure 2. The most significant difference was
observed for hTERT, where 75% of patients who were
hTERT positive without a tumor at cystoscopy recurred
within 24 months. In contrast only 25% of those who were
hTERT negative and had no tumor at cystoscopy recurred
within 24 months. The same tendency was found for
MCM5. Fifty-six percent (9/16) of the positives (at first
analysis considered false positive) recurred shortly after
urine sampling and when we considered the disease
course in the data analysis, they ended up as true positive.
Univariate Cox regression analysis also showed that both
hTERT and MCM5 were significantly associated with
recurrence free survival (hTERT: HR = 4.6, p < 0.001;
MCM5: HR = 2.7, p = 0.03). None of the risk factors for
recurrence (i.e. previous stage, grade, size, multiplicity and
CIS) were significantly associated with recurrence free sur-
vival in this group of patients. Multivariate Cox regression
analysis showed that hTERT and MCM5 were indepen-
dent prognostic markers for recurrence free survival when
stratifying for previous grade, multiplicity and CIS
(hTERT: HR = 8.5, p < 0.001; MCM5: HR = 4.2, p = 0.02).
No other variables were significantly associated with
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Figure 1 hTERT and MCM5 ROC curves. A: ROC curve for hTERT in combination with cytology grade 2 or grade 3 atypical cells and follow-up
information included in the classification. The area under the curve is 81%. B: ROC curve for MCM5 in combination with cytology grade 2 or
grade 3 atypical cells and follow-up information included in the classification.
Table 3 Sensitivity and specificity of the urine markers
when using cystoscopy as gold standard for detection of
bladder cancer
Sens. Spec. AUC OR 95%CI PPV NPV P(chi
2)
hTERT 62.5 72.9 0.68 4.48 2.09-9.58 71.4 64.2 < 0.001
PPP1CA 68.8 62.7 0.66 3.7 1.76-7.77 66.7 64.9 < 0.001
SENP1 56.3 78 0.67 4.55 2.08-9.94 73.5 62.2 < 0.001
MCM5 62.5 65.9 0.64 3.21 1.36-7.62 68.2 60 0.008
Cytology
ALL*
41.7 87.9 0.65 5.2 2.06-13.1 78.1 59.3 < 0.001
Cytology
Gr.2-3(Cyt2-3)
48.3 79.3 0.64 3.59 1.6-8 70.7 59.7 0.002
Cyt2-3
+hTERT**
73.3 74.1 0.74 7.88 3.49-17.8 74.6 72.9 < 0.001
Cyt2-3
+MCM5**
77.8 67.5 0.73 7.27 2.8-18.9 72.9 73 < 0.001
Cyt2-3+
SENP1**
65 74.1 0.70 5.32 2.42-11.7 72.2 67.2 < 0.001
Cyt2-3
+PPP1CA**
75 60.3 0.68 4.57 2.09-9.96 66.2 70 < 0.001
Cyt2-3
+MCM5
+hTERT***
77.8 67.5 0.73 7.27 2.8-18.9 72.9 73 < 0.001
* All atypical cells in the urine recorded as positive.
** One or both positive.
*** If only hTERT was positive then the combined score was classified as
negative.
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Page 4 of 7Table 4 Sensitivity and specificity of urine markers when including follow-up data for detection of bladder cancer
Sensitivity Specificity AUC OR 95% CI PPV NPV P-value
hTERT 62 84.1 0.73 8.63 3.47-21.4 87.5 55.2 < 0.001
MCM5 61 73.3 0.67 4.3 1.66-11.1 81.8 48.9 0.002
SENP1 53.2 84.1 0.69 6 2.43-14.7 85.7 50 < 0.001
PPP1CA 64.6 65.9 0.65 3.52 1.63-7.6 77.3 50.9 0.001
Cyt2-3* 42.7 100 0.71 100 50 < 0.001
MCM5+Cyt2-3* 73.2 75.9 0.75 8.59 3.09-23.8 85.4 59.5 < 0.001
hTERT+Cyt 2-3* 70.7 86 0.78 14.9 5.59-39.2 89.8 62.7 < 0.001
hTERT+SENP1** 68.4 75 0.72 6.48 2.85-14.7 83.1 56.8 < 0.001
hTERT+MCM5 71.2 66.7 0.69 4.94 1.94-12.6 80.8 54.1 0.001
hTERT+MCM5+Cyt2-3* 73.2 75.9 0.75 8.59 3.09- 23.8 85.4 59.5 < 0.001
* Positive cytology defined by atypical cells grade 2 or 3 in the urine.
**Considered positive if either SENP1 or hTERT or both are positive.
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Figure 2 Recurrence-free survival estimates. Kaplan-Meier plot of recurrence-free survival for hTERT (N = 65) (A) and MCM5 (N = 47) (B) alone
and in combination with cytology (C and D). E: Kaplan-Meier plot of recurrence-free survival based on cytology results. Only urine samples from
patients with no cystoscopy detectable tumors are included.
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lack of association between the risk factor for recurrence
and the later tumor recurrence events is probably
observed because of the limited number of urine samples
included in this analysis (non-recurrent visits only).
Discussion
Finding a way to diagnose bladder cancer recurrence
using a urine marker has been a major challenge in
many years. Here we aimed at making a simple test use-
ful on urine samples from every patient. A cross section
of patients was used from the clinic disregarding large
differences in disease courses and earlier treatment.
The most well characterized marker in this study was
hTERT. The urine expression has been studied previously
and impressive results with sensitivity levels of 92% and
specificity of 96% have been reported. In contrast to this
study, the patient population consisted only of untreated
bladder cancer patients in which a higher RNA concentra-
tion was expected in the urine [6] and thereby a higher
detection rate [23]. A urinary marker also needs to be
insensitive to benign conditions like infections and cysto-
lithiasis. Melissourgos et al. used a control group of 128
non-bladder cancer patients; false positive cases of hTERT
detection occurred in persons with benign prostate hyper-
plasia or cystolitiasis [6]. Cytology has an equivalent false
positive rate, but the false positives were associated with
bladder inflammation [6]. Surprisingly, hTERT mRNA is
not detected in cases where lymphocyte inflammation is
present, since telomerase enzymatic activity is up regu-
lated in activated lymphocytes. However, this enzymatic
up-regulation may just be a transient effect [6,8]. Another
large study of hTERT and hTR in urine of 465 subjects in
three different groups, bladder cancer, benign urologic
conditions and healthy controls has been conducted by
Weikert et al. [8]. Previous studies reported sensitivity
between 55.2- 91.8% and specificity between 85-96.1%. We
observed a comparable sensitivity of 62%, but the specifi-
city of 84.1% is a little lower [6,7]. This could be due to
the high number of low-grade Ta tumors in this study.
The data presented here gives hope for a non-invasive test
able to improve the current diagnostic regime, but there
are some problems when working with urine RNA, as it is
highly degradable and variation in cell content is large. We
compared the RNA concentration in the different samples
and found a significant difference, when comparing the
primary group, the recurrent group and the non-recurrent
group. The primary group had a much higher amount of
RNA as compared to the other groups. The non-recur-
rence and recurrence groups are rather similar in RNA
concentration. Van Rhijn et al. reported lower biomarker
sensitivity in patients who are under surveillance for blad-
der cancer compared to a cross sectional sampling of pri-
mary and surveillance patients, while their specificity was
not influenced [23]. In accordance with our results the
sensitivity increases with higher tumor grade. Okumura
et al. 2004 found the opposite correlation between hTERT
and tumor grade and suggested an alternative mechanism
that can immortalize cells [21]. SENP1 in our study was
included based on the same theory, since it is known that
in certain cancers maintain their telomeres by a telomer-
ase independent mechanism known as alternative length-
ening of telomeres (ALT) [27,28]. We examined the
possibility to increase the test using a molecular marker
for ALT in conjunction with expression of hTERT. SENP1
might serve as such a marker. We found that SENP1 was
positive in hTERT negative samples. Unfortunately diag-
nostic power of the combined analysis did not increase
compared to hTERT alone (Additional file 4).
Conclusions
With hTERT we should in theory have a marker unique
to tumor cells; while gaining telomerase function they
become immortal and insensitive to the normal senes-
cence and apoptosis signal. Normally, hTERT is not
seen in normal cells apart from germ- and stem cells.
SENP1 was included as a potential marker of alternative
lengthening of telomeres in the hTERT negative, but
immortalized cells and it was a significant biomarker in
our study. MCM5 has been characterized as highly
expressed in high grade tumors. Telomerase has been
suggested to be present in low grade tumors and these
two markers should, in theory, complement each other.
However, we did not observe an increase in accuracy of
the markers when combined.
In conclusion, the investigated candidates are promis-
ing but all have a lower specificity than cytology. They
have a better sensitivity, and a combination with cytol-
ogy may be an alternative to existing methods.
Additional material
Additional file 1: Clinical data for the patients in the study.
Additional file 2: Data for the examined urines in the study.
Additional file 3: Sensitivity and specificity when using a combined
tumor diagnosis using both cystoscopy verified recurrence and
atypical cells grade 2 or 3 in the urine.
Additional file 4: Marker sensitivity and specificity when stratified
for tumor grade.
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